William Y. Kim(@WilliamKimMD) 's Twitter Profileg
William Y. Kim

@WilliamKimMD

Prof of Med, Gen, Pharm UNC Chapel Hill. Physician-scientist, @wesleyan_u @BrownMedicine @BIDMC_IM @DanaFarber Alum. Working to cure #bladdercancer & #RCC.

ID:1938293942

linkhttps://unclineberger.org/kimlab/ calendar_today05-10-2013 17:15:57

567 Tweets

1,6K Followers

1,9K Following

Qing Zhang(@QingZhangLab) 's Twitter Profile Photo

jci.org/articles/view/…

Delighted to share our recent publication Journal of Clinical Investigation on the new function of VHL on regulating m6A signaling and mRNA stability in ccRCC tumorigenesis. 1/n

jci.org/articles/view/… Delighted to share our recent publication @jclinicalinvest on the new function of VHL on regulating m6A signaling and mRNA stability in ccRCC tumorigenesis. 1/n
account_circle
Matthew Herper(@matthewherper) 's Twitter Profile Photo

Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open statnews.com/2024/03/14/med…

account_circle
Markus Eckstein(@Markuseckstein3) 's Twitter Profile Photo

🎉🔬 The 10th episode is out.
➡️ Checkout for summary of all episodes🧪🔬‼️
x.com/markuseckstein…

After in we will now dive into specific variant urothelial/urothelial subtype histologies!

➡️ General overview on

account_circle
Dana-Farber Lank Center for Genitourinary Oncology(@DanaFarber_GU) 's Twitter Profile Photo

GU Research Digest for the week of February 3 - 9: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

GU Research Digest for the week of February 3 - 9: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!
account_circle
Liang Cheng, MD(@LiangChengMD) 's Twitter Profile Photo

Happy Friday! Happy Chinese New Year! Happy to share that our final version of our paper Modern Pathology is now available online at the following link:  sciencedirect.com/science/articl…  Congrats to Dr. Posada, our former Brown Pathology and Laboratory Medicine fellow, and our spectacular international team

Happy Friday! Happy Chinese New Year! Happy to share that our final version of our paper @ModernPathology is now available online at the following link:  sciencedirect.com/science/articl…  Congrats to Dr. Posada, our former @BrownPathology fellow, and our spectacular international team
account_circle
Andrea Apolo, M.D.(@apolo_andrea) 's Twitter Profile Photo

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer hmpgloballearningnetwork.com/site/onc/confe…

account_circle
UNC Lineberger(@UNC_Lineberger) 's Twitter Profile Photo

This , we honor the efforts of cancer researchers and providers -- locally and globally -- to end the burden of cancer. UNC Lineberger is dedicated to understanding the causes of cancer, and to use this knowledge to develop innovative treatments for our patients.

account_circle
Asociación Argentina de Oncología Clínica (AAOC)(@aaoncoclinica) 's Twitter Profile Photo

Como mejorar los resultados de los ICI en UC? William Y. Kim nos muestra como. El microambiente tumoral y su rol fundamental 🧬 .
Diferentes respuestas del TME según la QT neoadyuvante! 🔎

Como mejorar los resultados de los ICI en UC? @WilliamKimMD nos muestra como. El microambiente tumoral y su rol fundamental 🧬 . Diferentes respuestas del TME según la QT neoadyuvante! 🔎
account_circle
David B. Solit, MD(@DSolit) 's Twitter Profile Photo

Great to see this live. Thanks to Aphrothiti Hanrahan and Ziyu Chen as well as David Killock and the editorial staff for their extraordinary efforts. Very optimistic about the new RAF-based therapies in development.

account_circle
Thomas Flaig(@TomFlaigMD) 's Twitter Profile Photo

The National Comprehensive Cancer Network (NCCN) Bladder Cancer Guidelines v1.2024 are now available. It has been a very active time in bladder cancer therapeutic development. Important updates on the treatment of locally advanced/metastatic disease and in many other areas.
nccn.org/home

The @NCCN Bladder Cancer Guidelines v1.2024 are now available. It has been a very active time in bladder cancer therapeutic development. Important updates on the treatment of locally advanced/metastatic disease and in many other areas. #BladderCancer nccn.org/home
account_circle